Cargando…
Safety of inactivated SARS-CoV-2 vaccines in myasthenia gravis: A survey-based study
BACKGROUND: Vaccination remains the most effective measure to prevent SARS-CoV-2 infection and worse outcomes. However, many myasthenia gravis (MG) patients are hesitant to receive vaccine due to fear of worsening. METHODS: MG patients were consecutively enrolled in two MG centers in North China. Th...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9388926/ https://www.ncbi.nlm.nih.gov/pubmed/35990671 http://dx.doi.org/10.3389/fimmu.2022.923017 |
_version_ | 1784770321792892928 |
---|---|
author | Li, Hong-Yan Shao, Li-Yuan Song, Min Hu, Shi-Min Yue, Yao-Xian Li, Hai-Feng |
author_facet | Li, Hong-Yan Shao, Li-Yuan Song, Min Hu, Shi-Min Yue, Yao-Xian Li, Hai-Feng |
author_sort | Li, Hong-Yan |
collection | PubMed |
description | BACKGROUND: Vaccination remains the most effective measure to prevent SARS-CoV-2 infection and worse outcomes. However, many myasthenia gravis (MG) patients are hesitant to receive vaccine due to fear of worsening. METHODS: MG patients were consecutively enrolled in two MG centers in North China. The “worsening” after vaccination was self-reported by MG patients, and severity was measured with a single simple question. The general characteristics and disease status immediately prior to the first dose were compared between the worsening and non-worsening groups. Independent factors associated with worsening were explored with multivariate regression analysis. RESULTS: One hundred and seven patients were included. Eleven patients (10.3%) reported worsening after vaccination, including eight patients with mild or moderate worsening and three patients with severe worsening. Only one of them (0.9%) needed an escalation of immunosuppressive treatments. There were significant differences between the worsening and non-worsening groups in terms of Myasthenia Gravis Foundation of America classes immediately before the first dose and intervals since the last aggravation. Precipitating factors might contribute to the worsening in some patients. Logistic regression revealed that only interval since the last aggravation ≤6 months was associated with worsening after SARS-CoV-2 vaccination (P = 0.01, OR = 8.62, 95% CI: 1.93–38.46). CONCLUSION: SARS-CoV-2 vaccines (an overwhelming majority were inactivated vaccines) were found safe in milder Chinese MG patients who finished two doses. Worsening after vaccination was more frequently seen in patients who were presumed as potentially unstable (intervals since last aggravation ≤6 months). However, mild worsening did occur in patients who were presumed to be stable. Precipitating factors should still be sought and treated for better outcome. |
format | Online Article Text |
id | pubmed-9388926 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-93889262022-08-20 Safety of inactivated SARS-CoV-2 vaccines in myasthenia gravis: A survey-based study Li, Hong-Yan Shao, Li-Yuan Song, Min Hu, Shi-Min Yue, Yao-Xian Li, Hai-Feng Front Immunol Immunology BACKGROUND: Vaccination remains the most effective measure to prevent SARS-CoV-2 infection and worse outcomes. However, many myasthenia gravis (MG) patients are hesitant to receive vaccine due to fear of worsening. METHODS: MG patients were consecutively enrolled in two MG centers in North China. The “worsening” after vaccination was self-reported by MG patients, and severity was measured with a single simple question. The general characteristics and disease status immediately prior to the first dose were compared between the worsening and non-worsening groups. Independent factors associated with worsening were explored with multivariate regression analysis. RESULTS: One hundred and seven patients were included. Eleven patients (10.3%) reported worsening after vaccination, including eight patients with mild or moderate worsening and three patients with severe worsening. Only one of them (0.9%) needed an escalation of immunosuppressive treatments. There were significant differences between the worsening and non-worsening groups in terms of Myasthenia Gravis Foundation of America classes immediately before the first dose and intervals since the last aggravation. Precipitating factors might contribute to the worsening in some patients. Logistic regression revealed that only interval since the last aggravation ≤6 months was associated with worsening after SARS-CoV-2 vaccination (P = 0.01, OR = 8.62, 95% CI: 1.93–38.46). CONCLUSION: SARS-CoV-2 vaccines (an overwhelming majority were inactivated vaccines) were found safe in milder Chinese MG patients who finished two doses. Worsening after vaccination was more frequently seen in patients who were presumed as potentially unstable (intervals since last aggravation ≤6 months). However, mild worsening did occur in patients who were presumed to be stable. Precipitating factors should still be sought and treated for better outcome. Frontiers Media S.A. 2022-08-05 /pmc/articles/PMC9388926/ /pubmed/35990671 http://dx.doi.org/10.3389/fimmu.2022.923017 Text en Copyright © 2022 Li, Shao, Song, Hu, Yue and Li https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Immunology Li, Hong-Yan Shao, Li-Yuan Song, Min Hu, Shi-Min Yue, Yao-Xian Li, Hai-Feng Safety of inactivated SARS-CoV-2 vaccines in myasthenia gravis: A survey-based study |
title | Safety of inactivated SARS-CoV-2 vaccines in myasthenia gravis: A survey-based study |
title_full | Safety of inactivated SARS-CoV-2 vaccines in myasthenia gravis: A survey-based study |
title_fullStr | Safety of inactivated SARS-CoV-2 vaccines in myasthenia gravis: A survey-based study |
title_full_unstemmed | Safety of inactivated SARS-CoV-2 vaccines in myasthenia gravis: A survey-based study |
title_short | Safety of inactivated SARS-CoV-2 vaccines in myasthenia gravis: A survey-based study |
title_sort | safety of inactivated sars-cov-2 vaccines in myasthenia gravis: a survey-based study |
topic | Immunology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9388926/ https://www.ncbi.nlm.nih.gov/pubmed/35990671 http://dx.doi.org/10.3389/fimmu.2022.923017 |
work_keys_str_mv | AT lihongyan safetyofinactivatedsarscov2vaccinesinmyastheniagravisasurveybasedstudy AT shaoliyuan safetyofinactivatedsarscov2vaccinesinmyastheniagravisasurveybasedstudy AT songmin safetyofinactivatedsarscov2vaccinesinmyastheniagravisasurveybasedstudy AT hushimin safetyofinactivatedsarscov2vaccinesinmyastheniagravisasurveybasedstudy AT yueyaoxian safetyofinactivatedsarscov2vaccinesinmyastheniagravisasurveybasedstudy AT lihaifeng safetyofinactivatedsarscov2vaccinesinmyastheniagravisasurveybasedstudy |